Division of General Medicine and Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Cancer. 2018 Aug;124(16):3346-3354. doi: 10.1002/cncr.31566. Epub 2018 Jul 13.
Colorectal cancer (CRC) screening is effective but underused. Screening rates are lower among Medicaid beneficiaries versus other insured populations. No studies have examined mailed fecal immunochemical testing (FIT)-based outreach programs for Medicaid beneficiaries.
In a patient-level randomized controlled trial, a mailed CRC screening reminder plus FIT, sent from an urban health department to Medicaid beneficiaries, was compared with the same reminder without FIT. The reminder group could request FIT. Completed FIT kits were processed by the health department laboratory. Respondents were notified of normal results by mail. Abnormal results were given via phone by a patient navigator who provided counselling and assistance with follow-up care. The primary outcome was FIT return.
In all, 2144 beneficiaries at average CRC risk were identified, and there was no evidence of screening with Medicaid claims data. To the reminder+FIT group, 1071 were randomized, and 1073 were randomized to the reminder group; 307 (28.7%) in the reminder+FIT group and 347 (32.3%) in the reminder group were unreachable or ineligible (previous screening). The FIT return rate was significantly higher in the reminder+FIT group than the reminder group (21.1% vs 12.3%; difference, 8.8%; 95% confidence interval, 3.7%-13.9%; P < .01). Eighteen individuals (7.2%) who completed FIT tests had abnormal results, and 15 were eligible for follow-up colonoscopy; 66.7% (n = 10) completed follow-up colonoscopy.
A health department-based, mailed FIT program targeting Medicaid beneficiaries was feasible. Including a FIT kit resulted in greater screening completion than a reminder letter alone. Further research is needed to understand the comparative cost-effectiveness of these interventions.
结直肠癌(CRC)筛查是有效的,但使用率较低。与其他有保险的人群相比,医疗补助计划的受益人筛查率较低。没有研究调查过针对医疗补助受益人的邮寄粪便免疫化学检测(FIT)为基础的外展计划。
在一项患者水平的随机对照试验中,将城市卫生部门寄给医疗补助受益人的 CRC 筛查提醒加 FIT 与仅提供提醒进行比较。提醒组可以要求进行 FIT。卫生部门的实验室处理已完成的 FIT 试剂盒。通过邮件通知正常结果。通过提供咨询和帮助进行随访的患者导航员通过电话通知异常结果。主要结果是 FIT 返回。
共确定了 2144 名平均 CRC 风险的受益人,并且没有使用医疗补助索赔数据进行筛查的证据。对于提醒+FIT 组,随机分配了 1071 人,提醒组随机分配了 1073 人;提醒+FIT 组中有 307 人(28.7%)无法联系或不合格(以前的筛查),提醒组中有 347 人(32.3%)无法联系或不合格。提醒+FIT 组的 FIT 回复率明显高于提醒组(21.1%对 12.3%;差异 8.8%;95%置信区间 3.7%-13.9%;P<.01)。完成 FIT 测试的 18 名个体(7.2%)结果异常,15 名符合进行后续结肠镜检查的条件;有 66.7%(n=10)完成了后续结肠镜检查。
针对医疗补助受益人的基于卫生部门的邮寄 FIT 计划是可行的。与单独的提醒信相比,包含 FIT 试剂盒可提高筛查完成率。需要进一步研究来了解这些干预措施的相对成本效益。